Focus on Lipids Care

Back to articles

Statins’ cardiovascular benefits outweigh diabetes risk in primary prevention

KEY POINT

In patients with one or more major risk factors for developing diabetes, the cardiovascular and mortality benefits of rosuvastatin (Crestor—AstraZeneca) outweighed the risks of developing new-onset diabetes, according to a recent secondary analysis of the JUPITER trial (Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).